Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation

Acta Pharmacologica Sinica

Volumn 31, Issue 7, 2010, Pages 813-820

  Chen, Xiao Niao ^a   Xu, Jun ^b   Feng, Zhe ^c   Fan, Ming ^d   Han, Jing Yao ^a   Yang, Zhuo ^a  

^a NANKAI UNIVERSITY   (China)

^b Beijing ZhongGuanCun Middle School   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

calcium; endothelial nitric oxide synthase; nifedipine; nitric oxide; phosphatidylinositol 3 kinase; reactive oxygen species; simvastatin; vascular endothelial cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CALCIUM; MESSENGER RNA; NIFEDIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; WORTMANNIN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CALCIUM CELL LEVEL; CELL ASSAY; CELL PROTECTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN; UPREGULATION; WESTERN BLOTTING; CYTOLOGY; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; PHOSPHORYLATION; TOXICITY;

BLOTTING, WESTERN; CALCIUM CHANNEL BLOCKERS; DRUG INTERACTIONS; ENDOTHELIAL CELLS; HUMANS; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIFEDIPINE; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIMVASTATIN; UMBILICAL VEINS; UP-REGULATION;

EID: 77954522739     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.58     Document Type: Article

References (31)

1. Jiang JY, Wong MC, Zhang XH, Fung H, Griffths S, Mercer S. Profles of mortality among Chinese hypertensive patients in Hong Kong: a cohort study. J Hum Hypertens 2009; 23: 735-742
2. Matthys KE, Bult H. Nitric oxide function in atherosclerosis. Mediators Infamm 1997; 6: 3-21.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809
4. Noll G, Tschudi M, Nava E, Luscher TF. Endothelium and high blood pressure. Int J Microcirc Clin Exp 1997; 17: 273-279
5. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, patho-physiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142
6. Rabelink TJ, Luscher TF. Endothelial nitric oxide synthase: host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 2006; 26: 267-271
7. Zanchetti A. The antiatherogenic effects of antihypertensive drugs: experimental and clinical evidence. Clin Exp Hypertens A 1992; 14: 307-331
8. Lichtlen PR, Hugenholtz PG, Raffenbeul W, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet 1990; 335: 1109-1113 (Pubitemid 20159424)
9. Matsubara M, Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis 2005; 178: 57-66.
10. Deng HF, Xiong Y. Effect of pravastatin on impaired endothelium-dependent relaxation induced by lysophosphatidylcholine in rat aorta. Acta Pharmacol Sin 2005; 26: 92-98 (Pubitemid 40093245)
11. Ma FX, Liu LY, Xiong XM. Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta Pharmacol Sin 2003; 24: 1027-1032
12. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 1989; 87: 28S-38S.
13. Todd PA, Goa KL. Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990; 40: 583-607.
14. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003; 52: 777-783
15. 2-induced apoptosis through functional codependence between HO-1 and AKT. Arterioscler Thromb Vasc Biol 2006; 26: 2027-2034
16. Koneru S, Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Han Z, et al. Redox regulation of ischemic preconditioning is mediated by the differential activation of caveolins and their association with eNOS and GLUT-4. Am J Physiol Heart Circ Physiol 2007; 292: H2060-72.
17. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265-9269
18. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242
19. Hyndman ME, Parsons HG, Verma S, Bridge PJ, Edworthy S, Jones C, et al. The T-786→C mutation in endothelial nitric oxide synthase is associated with hypertension. Hypertension 2002; 39: 919-922
20. Mak IT, Boehme P, Weglicki WB. Protective effects of calcium channel blockers against free radical-impaired endothelial cell proliferation. Biochem Pharmacol 1995; 50: 1531-1534
21. Henrich D, Seebach C, Wilhelm K, Marzi I. High dosage of simvastatin reduces TNF-alpha-induced apoptosis of endothelial progenitor cells but fails to prevent apoptosis induced by IL-1beta in vitro. J Surg Res 2007; 142: 13-19
22. Ungvari Z, Csiszar A, Kaley G. Vascular infammation in aging. Herz 2004; 29: 733-740
23. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
24. 2+ infux upon hypoxia. J Cell Biochem 2000; 78: 458-464
25. Himmel HM, Whorton AR, Strauss HC. Intracellular calcium, currents, and stimulus-response coupling in endothelial cells. Hypertension 1993; 21: 112-2 7.
26. Cominacini L, Fratta Pasini A, Garbin U, Pastorino AM, Davoli A, Nava C, et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun 2003; 302: 679-684
27. Mason RP, Trumbore MW. Differential membrane interactions of calcium channel blockers. Implications for antioxidant activity. Biochem Pharmacol 1996; 51: 653-660
28. Lenasi H, Kohlstedt K, Fichtlscherer B, Mulsch A, Busse R, Fleming I. Amlodipine activates the endothelial nitric oxide synthase by altering phosphorylation on Ser1177 and Thr495. Cardiovasc Res 2003; 59: 844-853
29. Yamagishi S, Nakamura K, Takenaka K, Matsui T, Inoue H. Pleiotropic effects of nifedipine on atherosclerosis. Curr Pharm Des 2006; 12: 1543-1547
30. Yamagishi S, Nakamura K, Matsui T. Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. Curr Med Chem 2008; 15: 172-177
31. Thomas SR, Witting PK, Drummond GR. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008; 10: 1713-1765